G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations.
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Plerixafor (Primary) ; Sorafenib (Primary) ; Filgrastim
- Indications Acute myeloid leukaemia; Myeloid leukaemia
- Focus Adverse reactions
- 27 Mar 2017 Status changed from to completed.
- 23 Feb 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 13 Jan 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.